Free Trial
NASDAQ:ATHA

Athira Pharma Q1 2025 Earnings Report

Athira Pharma logo
$0.26 0.00 (-1.76%)
As of 05/9/2025 03:58 PM Eastern

Athira Pharma EPS Results

Actual EPS
-$0.23
Consensus EPS
-$0.20
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A

Athira Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Athira Pharma Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
Friday, May 9, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Athira Pharma's Q2 2025 earnings is scheduled for Tuesday, May 13, 2025

Athira Pharma Earnings Headlines

[FREE GIFT] New AI for retail traders
TradeAlgo has found a “backdoor way” for retail traders to profit from the AI arms race by developing its groundbreaking tech called Dark Flow AI. How it works is simple. AI scans through dark pools and alerts TradeAlgo members on companies with unusual activity. (Usually an indication of MAJOR institutions loading up shares.) Want to get informed of these alerts?
Athira Pharma Inc.
See More Athira Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Athira Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Athira Pharma and other key companies, straight to your email.

About Athira Pharma

Athira Pharma (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

View Athira Pharma Profile

More Earnings Resources from MarketBeat